Clinical trial
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of…
NCT00090324 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00090324 |
|---|---|
| Title | Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia |
| Official title | A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviated) |
| Acronym | ANCHOR 112 |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | quetiapine fumarate tablets |
| Enrollment | 249 |
| Start date | Sep 1, 2004 |
| Completion | Jun 1, 2007 |
| First posted | Aug 30, 2004 |
| Last update posted | Jan 4, 2013 |
| Countries | Germany, India, Malaysia, Philippines, Poland, Russia, Serbia, South Africa, Ukraine, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: